Dose-Escalation Study of Zongertinib in Patients with Advanced Non-Small Cell Lung Cancer and Solid Tumors with HER2 Aberrations

The primary objective of the study titled "Beamion LUNG-1" is to evaluate the efficacy and safety of different doses of **zongertinib** in individuals diagnosed with advanced **non-small cell lung cancer** and other **solid tumours** exhibiting **HER2 aberrations**. This investigation is clinically relevant as it aims to determine the optimal dosing regimen of zongertinib, which could potentially improve therapeutic outcomes and provide a targeted treatment option for patients with these specific genetic alterations in their tumors.

The clinical trial involves a total of **310 participants** diagnosed with **non-small cell lung cancer** and solid tumors with **HER2 aberrations**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, but they are likely to be individuals with the aforementioned medical conditions. Lifestyle considerations such as diet, physical activity, or habits are not detailed in the available data. The sponsor has not provided specific information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the efficacy and safety of zongertinib in patients with **non-small cell lung cancer** and solid tumors with HER2 aberrations. This is a Phase 1 trial, which is randomized, double-blind, and controlled, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial commenced on August 20, 2021, and is projected to conclude by March 30, 2026, encompassing a total duration of approximately 4 years and 7 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation, including medical history, physical examination, and necessary laboratory tests. Following successful screening, participants will be randomized into different dosing groups. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess the drug's effects, and collect data on safety and efficacy. These visits will include physical examinations, laboratory tests, and imaging studies as required. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the treatment's impact.

The expected length of participant involvement in the trial is contingent upon the individual's response to the treatment and the overall study timeline. Participants may be withdrawn from the study prematurely if they experience significant adverse effects, fail to comply with study protocols, or if the investigator deems it necessary for their safety. The trial is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the study duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

No specific details regarding the assessment of efficacy in the clinical trial are provided in the available data. Information on parameters or endpoints, methods, schedule for measuring, collecting, and analyzing efficacy parameters, as well as tools or instruments involved in efficacy assessments, is not included. The trial is identified as a Phase 1 study, with an estimated recruitment start date of August 20, 2021, and an estimated end date of March 30, 2026. Further details on efficacy assessment are not available in the provided data.